Neuphoria Therapeutics (NEUP) Enterprise Value (2020 - 2025)
Historic Enterprise Value for Neuphoria Therapeutics (NEUP) over the last 6 years, with Q4 2025 value amounting to -$22.3 million.
- Neuphoria Therapeutics' Enterprise Value fell 40355.91% to -$22.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$22.3 million, marking a year-over-year decrease of 40355.91%. This contributed to the annual value of -$14.3 million for FY2025, which is N/A changed from last year.
- Latest data reveals that Neuphoria Therapeutics reported Enterprise Value of -$22.3 million as of Q4 2025, which was down 40355.91% from -$13.7 million recorded in Q3 2025.
- Neuphoria Therapeutics' Enterprise Value's 5-year high stood at -$4.4 million during Q4 2024, with a 5-year trough of -$29.4 million in Q4 2021.
- In the last 5 years, Neuphoria Therapeutics' Enterprise Value had a median value of -$14.3 million in 2025 and averaged -$16.2 million.
- In the last 5 years, Neuphoria Therapeutics' Enterprise Value skyrocketed by 4926.37% in 2023 and then plummeted by 40355.91% in 2025.
- Quarter analysis of 5 years shows Neuphoria Therapeutics' Enterprise Value stood at -$29.4 million in 2021, then increased by 18.22% to -$24.0 million in 2022, then soared by 49.26% to -$12.2 million in 2023, then skyrocketed by 63.78% to -$4.4 million in 2024, then plummeted by 403.56% to -$22.3 million in 2025.
- Its Enterprise Value stands at -$22.3 million for Q4 2025, versus -$13.7 million for Q3 2025 and -$14.3 million for Q2 2025.